Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Sees Significant Increase in Short Interest

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) was the target of a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 119,700 shares, a growth of 93.4% from the February 13th total of 61,900 shares. Based on an average daily trading volume, of 4,130,000 shares, the days-to-cover ratio is presently 0.0 days. Approximately 6.5% of the company’s shares are short sold.

Hedge Funds Weigh In On Cyclerion Therapeutics

An institutional investor recently bought a new position in Cyclerion Therapeutics stock. Renaissance Technologies LLC bought a new position in shares of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 10,611 shares of the company’s stock, valued at approximately $34,000. Renaissance Technologies LLC owned approximately 0.39% of Cyclerion Therapeutics at the end of the most recent quarter. 75.62% of the stock is owned by institutional investors and hedge funds.

Cyclerion Therapeutics Trading Up 2.4 %

Shares of Cyclerion Therapeutics stock opened at $2.53 on Friday. The company has a market capitalization of $6.86 million, a PE ratio of -2.07 and a beta of 2.09. Cyclerion Therapeutics has a 12 month low of $1.27 and a 12 month high of $9.47. The stock’s fifty day simple moving average is $3.05 and its 200 day simple moving average is $2.90.

Cyclerion Therapeutics (NASDAQ:CYCN) last issued its quarterly earnings data on Tuesday, March 4th. The company reported $0.22 EPS for the quarter. The business had revenue of $1.81 million for the quarter.

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc, a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc for the treatment of rare kidney disease.